CN101987108A - 一种驱除动物体内外寄生虫的复方注射剂及其制备方法 - Google Patents
一种驱除动物体内外寄生虫的复方注射剂及其制备方法 Download PDFInfo
- Publication number
- CN101987108A CN101987108A CN 200910069942 CN200910069942A CN101987108A CN 101987108 A CN101987108 A CN 101987108A CN 200910069942 CN200910069942 CN 200910069942 CN 200910069942 A CN200910069942 A CN 200910069942A CN 101987108 A CN101987108 A CN 101987108A
- Authority
- CN
- China
- Prior art keywords
- ivermectin
- praziquantel
- repelling
- compound injection
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 26
- 239000007924 injection Substances 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 241001465754 Metazoa Species 0.000 title claims abstract description 16
- 230000001846 repelling effect Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 244000045947 parasite Species 0.000 title abstract description 10
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 38
- 229960002418 ivermectin Drugs 0.000 claims abstract description 38
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960002957 praziquantel Drugs 0.000 claims abstract description 32
- 239000003120 macrolide antibiotic agent Substances 0.000 claims abstract description 7
- 230000000507 anthelmentic effect Effects 0.000 claims description 15
- 244000078703 ectoparasite Species 0.000 claims description 9
- 244000079386 endoparasite Species 0.000 claims description 9
- 238000010254 subcutaneous injection Methods 0.000 claims description 9
- 239000007929 subcutaneous injection Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 14
- 238000001228 spectrum Methods 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000000295 complement effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 201000002266 mite infestation Diseases 0.000 abstract description 2
- 206010000351 Acariasis Diseases 0.000 abstract 1
- 241001136249 Agriotes lineatus Species 0.000 abstract 1
- 241001465677 Ancylostomatoidea Species 0.000 abstract 1
- 241000244203 Caenorhabditis elegans Species 0.000 abstract 1
- 241000078380 Cardiofilaria Species 0.000 abstract 1
- 241000193880 Demodex folliculorum Species 0.000 abstract 1
- 241000869417 Trematodes Species 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- 230000002141 anti-parasite Effects 0.000 description 11
- 239000005645 nematicide Substances 0.000 description 7
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000157855 Cinchona Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003096 antiparasitic agent Substances 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000002333 glycines Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 229960000948 quinine Drugs 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 235000001258 Cinchona calisaya Nutrition 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000921 anthelmintic agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- LAOOXBLMIJHMFO-UHFFFAOYSA-N 1-[2-(diethylamino)ethylamino]-4-methylthioxanthen-9-one;hydron;chloride Chemical compound Cl.S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC LAOOXBLMIJHMFO-UHFFFAOYSA-N 0.000 description 2
- 241001147672 Ancylostoma caninum Species 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 229930192734 Avilamycin Natural products 0.000 description 2
- 239000004190 Avilamycin Substances 0.000 description 2
- 102100032559 Clathrin light chain B Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000942271 Homo sapiens Clathrin light chain B Proteins 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 description 2
- 229960005185 avilamycin Drugs 0.000 description 2
- 235000019379 avilamycin Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001843 schistosomicidal effect Effects 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 240000006487 Aciphylla squarrosa Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001511271 Ancylostoma braziliense Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000467053 Capillaria aerophila Species 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- 241000288027 Chrysolophus pictus Species 0.000 description 1
- 235000021513 Cinchona Nutrition 0.000 description 1
- 241000489438 Cinchona pubescens Species 0.000 description 1
- 235000006768 Cinchona succirubra Nutrition 0.000 description 1
- 241001327965 Clonorchis sinensis Species 0.000 description 1
- 201000000077 Cysticercosis Diseases 0.000 description 1
- 208000020693 Demodicidosis Diseases 0.000 description 1
- 241000243988 Dirofilaria immitis Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000283087 Equus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000002163 Mesapamea fractilinea Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 241001468227 Streptomyces avermitilis Species 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000004441 taeniasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种用于驱除动物体内外寄生虫的复方注射剂及其制备方法。该复方注射剂主要由伊维菌素和吡喹酮组成。伊维菌素是十六元大环内酯类防治动物体内外寄生虫的特效药,能特效防治心丝虫,高效防治钩虫、圆虫、鞭虫、蛔虫等体内寄生虫,以及毛囊虫、疥癣、虱、跳蚤等体外寄生虫;吡喹酮对动物体内的线虫、吸虫、绦虫有效。伊维菌素和吡喹酮驱虫谱互补,通过两种药物的组合,扩大了驱虫谱,提高了一次性驱虫效果。本发明还提供了该复方注射剂的制备方法,本发明制备的注射剂用于皮下注射,药效持续时间长。
Description
技术领域
本发明属于兽药技术领域,特别涉及一种驱除动物体内外寄生虫的复方注射剂及其制备方法。
背景技术
驱虫药物发展历史悠久,远在2000多年前,我国的第一部本草《神农本草经》共列了30多种驱虫药物,常山治疟及楝实、雷丸、贯众等成为世界上最早记载驱(杀)虫药物。芜荑、茱萸、石榴根、狼牙、槟榔、南瓜子、榧子等驱虫药至今仍在使用。
17世纪30年代,西班牙人在秘鲁发现金鸡钠(cinchona)树皮能治疗疟疾,这为抗寄生虫药物向现代药物学发展打开了一扇窗户。1820年分离出金鸡钠树皮的主要生物碱-奎宁(quinine),在近两个世纪中奎宁在为治疗和预防疟疾中发挥了重要作用。1944年化学合成奎宁成功,这与磺胺等近代化学合成药物一起揭开了抗寄生虫药物的新时代。随着新技术和方法的应用,抗寄生虫病药物不断更新,化学合成及半合成药物成为抗寄生虫药物主流和研究方向。目前一般认为理想的抗寄生虫药物是:无毒、副作用;广谱高效;价格低廉、使用方便;不影响机体免疫力;药物及代谢产物不污染环境。对于食品动物用抗寄生虫药还要求无残留。目前广泛应用的动物抗寄生虫药吡喹酮已作为广谱杀吸虫、绦虫药物;伊维菌素(ivermectin)具有高效、低毒、抗虫谱广等特点,但是对吸虫、绦虫作用差。为了进一步扩大驱虫谱,增强驱虫效果,特研制二者的复方注射剂。
复方注射剂组分驱虫效果介绍:
1、伊维菌素(Ivermcctin):是由阿维链霉菌(streptomyces avermitilis)发酵产生的半合成大环内酯类多组分抗生素。主要含伊维菌素B1(B1a+B1b)不低于93%,其中B1a不得少于85%。伊维菌素B1即22,23-双氢阿维菌素B1
【药理】
(1)药效学伊维菌素是新型的广谱、高效、低毒抗生素类抗寄生虫药,对体内外寄生虫特别是线虫和节肢动物均有良好驱杀作用。但对绦虫、吸虫及原生动物无效。
大环内酯类抗寄生虫药对线虫及节肢动物的驱杀作用,在于增加虫体的抑制性递质γ-氨基丁酸〔GABA)的释放,以及打开谷氨酸控制的Cl-通道,增强神经膜对Cl-的通透性,从而阻断神经信号的传递,最终神经麻痹,使肌肉细胞失去收缩能力,而导致虫体死亡。
由于吸虫和绦虫不以GABA为传递递质,并且缺少受谷氨酸控制的Cl-通道。故本类药物对其无效。哺乳动物的外周神经递质为乙酰胆碱,GABA虽分布于中枢神经系统,但由于本类药物不易透过血脑屏障,而对其影响极小,因此使用时就比较安全。
本类药物影响寄生虫生殖的机理还不太清楚,但能使蜱减少产卵,反刍兽线虫虫卵形态异常和使丝状线虫(雄、雌性)不育。
(2)药动学伊维菌素的药代动力学因畜种、剂型和给药途径不同而有明显差异。以血浆半衰期为例,给牛、绵羊静脉注射300μg/kg量,t1/2虽然差别不大(分别为2.8天和2.7天),但羊的血浆浓度较低是由于表观分布容积大于牛所致。伊维菌素在犬体内排泄较快(t1/2=1.6~1.8天),猪的半衰期长达4天。
犬内服(100μg/kg)片剂,2~4h内血药达峰值(40ng/mL)。猪血药峰值到达时间,内服(0.5天)比皮下注射(2天)快,但皮下注射的生物利用度比内服要高得多,通常内服时的生物利用度仅为注射法的41%。
两种不同剂型(糊剂和水性微胞专用剂型)的伊维菌素给马内服,血药峰值出现时间,不仅水性微胞制剂(4~5h)比糊剂(15h)快得多,而且生物利用度亦高。(糊剂仅为水性微胞剂的20%)。
吸收后伊维菌素广泛分布于全身组织,并以肝脏和脂肪组织中浓度最高。伊维菌素通常在肝脏中氧化成代谢产物。
伊维菌素在5~6天内经粪便排泄的占90%以上,经尿排泄仅占0.5%~2%。
犬、猫(按6~12μg/kg量)用于防治犬心丝虫微丝蚴感染,我国可试用50μg/kg内服法治疗心丝虫微丝蚴虫感染(成虫无效)。临床试验证实,高剂量伊维菌素对犬多种寄生虫有高效,如一次皮下注射50μg/kg对犬钩口线虫、巴西钩口线虫、欧洲犬钩口线虫,100μg/kg对犬鞭虫,200μg/kg对犬弓首蛔虫成虫及第四期幼虫均有极佳驱只效果。对狮弓蛔虫,按200μg/kg量,皮下注射疗效仅69%,而内服则达95%。本品一次皮下注射,对犬寄生于肺部的嗜气毛细线虫(200μg/kg)、奥氏欧斯勒线虫(400μg/kg)也有极佳驱除效果。内服或皮下注射200μg/kg,两周后再用一次,对肠道粪类圆线虫(第3期幼虫除外)有效率95%~100%。
伊维菌素对犬、猫的某些节肢动物感染也有效,犬、猫皮下注射200μg/kg剂量,两周后再用一次能排除耳螨、疥螨、犬肺刺螨的感染。按300μg/kg量,连用两次(间隔2周)对姬螯螨感染也很有效。治疗犬蠕形螨病最好按600μg/kg皮下注射量,间隔7天.连用5次。
【药物相互作用】伊维菌素商品制剂中含有的不同佐剂能影响药物的作用,如绵羊内服含吐温-80做佐剂的制剂,伊维菌素用量达4000μg/kg时,仍很安全,但若以丙二醇做佐剂时则使绵羊持续3天出现共济失调和血红蛋白尿。美国含吐温-80做佐剂的依维菌素注射剂是马属动物专用商品制剂,但不能用于犬,否则亦极不安全。
3.吡喹酮
吡喹酮对血吸虫、绦虫、囊虫、华支睾吸虫、肺吸虫、姜片虫均有效。对虫体可起两种主要药理作用:
(1)虫体肌肉发生强直性收缩而产生痉挛性麻痹:血吸虫接触低浓度吡喹酮后仅20秒钟虫体张力即增高,血药浓度达1mg/L以上时,虫体瞬即强烈挛缩。虫体肌肉收缩可能与吡喹酮增加虫体细胞膜的通透性,使细胞内钙离子丧失有关。
(2)虫体皮层损害与宿主免疫功能参与:吡喹酮对虫体皮层有迅速而明显的损伤作用,引起合胞体外皮肿胀,出现空泡,形成大疱,突出体表,最终表皮糜烂溃破,分泌体几乎全部消失,环肌与纵肌亦迅速先后溶解。在宿主体内,服药后15分钟即可见虫体外皮空泡变性。皮层破坏后,影响虫体吸收与排泄功能,更重要的是其体表抗原暴露,从而易遭受宿主的免疫攻击,大量嗜酸粒细胞附着皮损处并侵入,促使虫体死亡。此外,吡喹酮还能引起继发性变化,使虫体表膜去极化,皮层碱性磷酸酶活性明显降低,致使葡萄糖的摄取受抑制,内源性糖原耗竭。吡喹酮还可抑制虫体核酸与蛋白质的合成。
药代动力学:
黄牛静注、肌注和内服吡喹酮的药动学与生物利用度
6头成年健康黄牛按10mg/kg剂量单次快速静注吡喹酮,另6头成年健康黄牛根据交叉试验设计法按10mg/kg剂量单次肌注、30mg/kg剂量内服吡喹酮进行药动学与生物利用度试验。利用高效液相色谱法测定血浆中吡喹酮原药的质量浓度、其检测限为25μg/L。房室模型分析表明,静注给药后的药时数据符合无吸收二室开放模型,其分布半衰期(t1/2α)、消除半衰期(t1/2β)、表观分布容积(Vd),总体清除率(ClB)、药时曲线下面积(AUC)分别为(0.25±0.03)h、(1.28±0.20)h,(2.11±0.38)L/kg,(1.14±0.10)L/(kg·h)和(8.79±0.74)mg/(L·h)。肌注的药时数据符合有吸收一室开放模型,主要药动学参数吸收半衰期(t1/2ka),消除半衰期(t1/2ke)、药时曲线下面积(AUC)、达峰时间(tmax),峰浓度(Cmax)和生物利用度(F)分别为(0.40±0.17)h,(4.65±0.91)h,(6.85±1.02)mg/(L·h),(1.33±0.52)h,(0.83±0.08)mg/L和77.93%,内服给药后符合有吸收一室开放模型,吸收不规则,其药动学参数t1/2ka,t1/2ke,AUC,Cmax和F分别为(1.08±0.13)h,(6.81±1.26)h,(8.51±1.78)mg/(L·h),(4.331.36)h,(0.70±0.08)mg/L和32.31%。结果表明,肌注给药吸收良好,而内服吸收不良,肌注的F为内服后的2.5倍,差异极显著(P<0.01)。
4.复方制剂的研究进展
伊维菌素等大环内酯类药物侧重于动物体内的线虫和皮肤内寄生的节肢类寄生虫,但对吸虫、绦虫无效;吡喹酮对动物体内的线虫、吸虫、绦虫有效,但对皮肤内寄生的节肢类寄生虫无效。所以二者驱虫谱互补,联合使用扩大了驱虫谱,提高了一次性驱虫效果。2007年内蒙古华奥科兴药业有限公司的复方伊维菌素(伊维菌素、氯氰碘柳胺钠)上市。它可明显增加寄生虫线粒体的渗透性,通过对氧化磷酸化的解偶作用发挥驱虫作用。其对家畜的肝片吸虫、前后盘吸虫及节肢动物的幼虫有非常好的驱杀活性,扩大复方制剂的抗虫谱和驱虫效力。另外,由于大环内酯类抗寄生虫药物与其它抗寄生虫药物之间的作用机制不同,因而该类药物与其它抗寄生虫药物之间不存在交叉耐药性,应该轮换交替用药。
通过两种药物的组合,可以达到拓宽驱虫谱的目的,一次投药同时驱除体内外寄生虫,使用方便,简化了驱虫模式,一定程度上满足了临床的需要。
发明内容
1、本发明的一个目的是提供一种用于驱除动物体内外寄生虫的复方注射剂,其特征在于组方由大环内酯类驱虫药、吡喹酮组成。
2、本发明的另一个目的是提供一种优选注射剂组方,此组方由伊维菌素和吡喹酮组成。其特征在于每支注射剂(5ml/支)中含有伊维菌素0.03-0.06g、吡喹酮0.15-0.30g。含量优选伊维菌素0.05g、吡喹酮0.25g,皮下注射剂量为0.1ml/kg。
3、本发明的另外一个目的还提供了该复方注射剂的制备方法。
本发明是通过下述步骤实现的:
本发明复方制剂的制备方法包括称取处方量原料药伊维菌素、吡喹酮,用丙二醇加热溶解,加苯甲醇7.5ml,加入配制器中,用适量精制豆油缓慢稀释至1000ml,上述溶液混合均匀,粗滤、精滤、灌装封口、灭菌、灯检、包装入库。
具体实施方式
实施例1
(1)处方(1000ml)
伊维菌素6g、吡喹酮30g、苯甲醇7.5ml、丙二醇150ml
(2)工艺
称取原料药伊维菌素6g、吡喹酮30g,用丙二醇加热溶解,加入7.5ml苯甲醇,加入配置器中,用适量的精制豆油缓慢稀释至1000ml,上述溶液混合均匀,粗滤、精滤、灌装封口、灭菌、灯检、包装入库。
实施例2
(1)处方(1000ml)
伊维菌素10g、吡喹酮50g、苯甲醇7.5ml、丙二醇150ml
(2)工艺
称取原料药伊维菌素10g、吡喹酮50g,用丙二醇加热溶解,加7.5ml苯甲醇,加入配置器中,用适量的精制豆油缓慢稀释至1000ml,上述溶液混合均匀,粗滤、精滤、灌装封口、灭菌、灯检、包装入库。
实施例3
(1)处方(1000ml)
伊维菌素12g、吡喹酮60g、苯甲醇7.5ml、丙二醇150ml
(2)工艺
称取原料药伊维菌素10g、吡喹酮50g,用丙二醇加热溶解,加7.5ml苯甲醇,加入配置器中,用适量的精制豆油缓慢稀释至1000ml,上述溶液混合均匀,粗滤、精滤、灌装封口、灭菌、灯检、包装入库。
实施例4:
以上述实施例2制备的注射剂为例,进行临床疗效试验,进一步说明本发明药物的治疗效果。【每支注射剂(5ml/支)中含有伊维菌素0.05g、吡喹酮0.25g,皮下注射剂量为0.1ml/kg】
选择病史、病情相当的患病猪100头随机分为2组,分别为试验组和对照组,每组50头。试验组给予本发明实施例2注射剂,一日1次,连用3天;对照组用阿维菌素注射剂,一日1次,连用3天。
试验结果:
表1两组药物疗效比较
试验证明,两组猪治疗后病情均有明显改善。治疗组治愈率和总有效率分别为92.0%和100%,对照组分别为60%和100%,两组之间治愈率差异极显著(P<0.01);可见伊维菌素、吡喹酮两种药物组合而制成的复方注射剂可以拓宽驱虫谱,增强驱除动物体内外寄生虫的能力,使用方便,药效确切。
Claims (3)
1.一种用于驱除动物体内外寄生虫的复方注射剂,其特征在于组方由大环内酯类驱虫药和吡喹酮组成,其中大环内酯类驱虫药优选伊维菌素。
2.根据权利要求1所述的一种用于驱除动物体内外寄生虫的复方注射剂,其特征在于每支注射剂(5ml/支)中含有伊维菌素0.03-0.06g、吡喹酮0.15-0.30g。
3.根据权利要求1、2所述的一种用于驱除动物体内外寄生虫的复方注射剂,其特征在于每支注射剂(5ml/支)中含量优选伊维菌素0.05g、吡喹酮0.25g,皮下注射剂量为0.1ml/kg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910069942 CN101987108A (zh) | 2009-07-30 | 2009-07-30 | 一种驱除动物体内外寄生虫的复方注射剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910069942 CN101987108A (zh) | 2009-07-30 | 2009-07-30 | 一种驱除动物体内外寄生虫的复方注射剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101987108A true CN101987108A (zh) | 2011-03-23 |
Family
ID=43744028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910069942 Pending CN101987108A (zh) | 2009-07-30 | 2009-07-30 | 一种驱除动物体内外寄生虫的复方注射剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101987108A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228662A (zh) * | 2011-06-15 | 2011-11-02 | 党学云 | 一种治疗血丝虫病的药物及其制备方法 |
CN103417559A (zh) * | 2012-05-15 | 2013-12-04 | 北京中农大动物保健品技术研究院 | 含伊维菌素和吡喹酮的兽用复方混悬注射液及其制备方法 |
-
2009
- 2009-07-30 CN CN 200910069942 patent/CN101987108A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228662A (zh) * | 2011-06-15 | 2011-11-02 | 党学云 | 一种治疗血丝虫病的药物及其制备方法 |
CN103417559A (zh) * | 2012-05-15 | 2013-12-04 | 北京中农大动物保健品技术研究院 | 含伊维菌素和吡喹酮的兽用复方混悬注射液及其制备方法 |
CN103417559B (zh) * | 2012-05-15 | 2016-07-13 | 北京中农大动物保健品技术研究院 | 含伊维菌素和吡喹酮的兽用复方混悬注射液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI352592B (en) | Anthelmintic combination | |
Yang | Acute human toxicity of macrocyclic lactones | |
CN103623071B (zh) | 一种兽用强效驱虫药物及其制备方法 | |
Fang et al. | Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio | |
Sulik et al. | Antiparasitic activity of ivermectin: Four decades of research into a “wonder drug” | |
EP2310018B1 (de) | Verwendung von nifurtimox zur behandlung der giardiasis | |
CA1337276C (en) | Anticoccidial composition | |
Rairat et al. | Pharmacokinetics, optimal dosages and withdrawal time of florfenicol in Asian seabass (Lates calcarifer) after oral administration via medicated feed | |
EP2310017B1 (de) | Nifurtimox zur behandlung von durch trichomonadida hervorgerufenen krankheiten | |
CN101987108A (zh) | 一种驱除动物体内外寄生虫的复方注射剂及其制备方法 | |
CN101933929A (zh) | 一种驱除犬、猫体内外寄生虫的复方制剂及其制备方法 | |
US5215993A (en) | Anticoccidial compositions | |
CN101244164A (zh) | 一种预防和治疗仔猪水肿病的药物 | |
KR20100025958A (ko) | 송아지의 설사치료용 조성물 | |
CN111514157A (zh) | 组合物在制备兽用抗寄生虫病药物中的应用、兽用抗寄生虫病的透皮溶液及其制备方法 | |
CN103356714A (zh) | 一种兽用含阿苯达唑和伊维菌素的复方药物组合物 | |
CN101669959A (zh) | 治疗畜禽肠道疾病的药物组合物及其制备方法和应用 | |
KR102374820B1 (ko) | 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물 | |
BG61064B1 (bg) | Лекарствено средство за обезпаразитяване на животни | |
Coop et al. | The use of macrocyclic lactones to control parasites of sheep and goats. | |
EP2744495B1 (en) | Anthelmintic formulations and treatments | |
Monahan et al. | The use of macrocyclic lactones to control parasites of horses. | |
Watson | Praziquantel | |
CN106344582A (zh) | 一种抗寄生虫药物组合物及应用 | |
Ocampo et al. | Efficacy of a pharmaceutical preparation based on glycyrrhizic acid in a challenge study of white spot syndrome in white shrimp (Litopenaeus vannamei) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110323 |